Innovent Biologics Inc. has received regulatory approval from China's National Medical Products Administration (NMPA) for TABOSUN® (ipilimumab N01 injection), the first domestic cytotoxic lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody. The approval is for use in combination with TYVYT® (sintilimab injection) as a neoadjuvant treatment for patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. This dual-immunotherapy regimen is the first and only approved globally for neoadjuvant treatment of colon cancer, addressing a significant unmet clinical need and offering a new therapeutic option for patients in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN53695) on December 25, 2025, and is solely responsible for the information contained therein.